Alembic Pharmaceuticals Limited (NSE:APLLTD)
India
· Delayed Price · Currency is INR | Market Cap | 172.90B |
| Revenue (ttm) | 66.72B |
| Net Income (ttm) | 5.83B |
| Shares Out | 196.56M |
| EPS (ttm) | 29.68 |
| PE Ratio | 29.64 |
| Forward PE | 24.18 |
| Dividend | 11.00 (1.25%) |
| Ex-Dividend Date | Jul 15, 2024 |
| Volume | 52,405 |
| Average Volume | 188,558 |
| Open | 886.90 |
| Previous Close | 879.60 |
| Day's Range | 880.00 - 897.90 |
| 52-Week Range | 725.20 - 1,303.90 |
| Beta | 0.47 |
| RSI | 50.59 |
| Earnings Date | May 8, 2025 |
About Alembic Pharmaceuticals
Alembic Pharmaceuticals Limited develops, manufactures, and markets pharmaceutical products in India and internationally. The company provides branded specialty medicines in various therapeutic areas, such as cardiology, gynecology, gastrology, ophthalmology, dermatology, nephrology/urology, orthopedics, anti-infective, cold and cough, veterinary, and anti-diabetic; generics formulations in oral solids, oncology oral solids and injectables, general injectables and ophthalmic products, dermatology, and oral suspension; and active pharmaceutical ... [Read more]
Financial Performance
In 2024, Alembic Pharmaceuticals's revenue was 66.72 billion, an increase of 7.12% compared to the previous year's 62.29 billion. Earnings were 5.83 billion, a decrease of -5.26%.
Financial StatementsNews
Alembic Pharma Q4 profit falls 12%, revenue rises 17%
Alembic Pharmaceuticals experienced a 12.1% dip in Q4 net profit, reaching Rs 156.63 crore, despite a 16.7% surge in revenue to Rs 1,769.64 crore. While India formulations and US revenue showed growth...
Alembic Pharmaceuticals shares drop 2% as Q4 net profit falls 11.9% YoY to Rs 156.89 crore
Alembic Pharmaceuticals saw a dip of over 2% in its shares following the announcement of Q4FY25 results. As of 2:08 PM, the shares were trading 1.94% down at Rs 887.85. Despite this, the company repor...
Alembic Pharmaceuticals Q4 Results: Revenue rises 16.7% YoY to ₹1,769 crore, Net profit down 11.96% YoY
Alembic Pharmaceuticals Ltd announced its financial results for the fourth quarter of FY25, reporting a mixed set of numbers. The company posted a net profit of ₹157 crore, down 11.8% year-on-year (Yo...
Alembic Pharma gets USFDA final nod for Ticagrelor 90 mg, tentative approval for 60 mg
Alembic Pharmaceuticals Limited announced on May 2, 2025, that it has received final approval from the US Food and Drug Administration (USFDA) for its Ticagrelor Tablets, 90 mg, and tentative approval...
Alembic Pharma share price jumps 3% after USFDA issues EIR from for Panelav plant
Alembic Pharmaceuticals saw a 3% surge in its stock price after receiving a favorable Establishment Inspection Report (EIR) from the US Food and Drug Administration (FDA). The report follows an inspec...
Stocks to watch today: Bajaj Finance, Infosys, Alembic Pharma, IndiaMART, Schaeffler India, CEAT in focus after key updates
Indian equities are expected to see stock-specific action on Wednesday as a host of companies reported quarterly results or announced corporate updates after market hours yesterday. Several firms acro...
Alembic Pharmaceuticals gets USFDA final approval for Carbamazepine tablets USP 200 mg
Alembic Pharmaceuticals has received final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Carbamazepine Tablets USP, 200 mg. These tablet...
Alembic Pharmaceuticals gets USFDA final approval for Pantoprazole Sodium for Injection, 40 mg/vial
Alembic Pharmaceuticals Limited has announced the receipt of Final Approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Pantoprazole Sodium for I...
Pharma and hospital stocks in focus today: Alembic Pharma, Gland Pharma, Apollo Hospital, Fortis Healthcare, Dr Reddy’s [March 24, 2025]
Pharma and hospital-related stocks are seeing heightened investor interest today, March 24, 2025, following key developments. Alembic Pharma announced the successful completion of a US FDA inspection ...
Top stocks to watch today, March 24: Alembic Pharma, Godrej Properties, NCC, Adani Green, Reliance Industries and more
Indian equity markets continued their stellar run, marking their best weekly performance in years. Investors shrugged off global uncertainties and snapped up undervalued stocks, pushing the benchmarks...
Alembic Pharmaceuticals completes USFDA inspection at Karakhadi API-III facility with zero observations
Alembic Pharmaceuticals Limited has successfully concluded a scheduled inspection by the United States Food and Drug Administration (USFDA) at its API-III manufacturing facility located in Karakhadi, ...
JSW Energy, Coffee Day, Alembic Pharma, Zota Health Care among stocks to watch today in business expansions
A few companies have made significant business moves that are expected to impact their growth trajectory. JSW Energy has received Competition Commission of India (CCI) approval for acquiring 100% shar...
Alembic Pharma shares drop 2.6% after US FDA issues one observation for Vadodara unit
Alembic Pharmaceuticals Limited saw its shares decline by 2.6% following the conclusion of a scheduled inspection by the United States Food and Drug Administration (USFDA) at its Bioequivalence Facili...
Alembic Pharmaceuticals receives form 483 with one procedural observation after US FDA inspection at Vadodara facility
Alembic Pharmaceuticals Limited successfully completed a scheduled inspection by the United States Food and Drug Administration (USFDA) at its Bioequivalence Facility in Vadodara from March 3 to March...
Stocks to watch today: M&M, BHEL, Zydus Life, Alembic Pharma, and PCBL in focus on Feb 17, 2025
Several stocks are in focus today based on key developments beyond Q3 earnings. M&M, BHEL, Zydus Life, Alembic Pharmaceuticals, and PCBL are among the notable companies making headlines. Key updates: ...
Alembic Pharmaceuticals receives USFDA approval for Brexpiprazole tablets
Alembic Pharmaceuticals Limited has achieved final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Brexpiprazole Tablets. The approved stren...
Alembic Pharmaceuticals shares surge nearly 3% on USFDA approval for Divalproex Sodium Capsules
Shares of Alembic Pharmaceuticals saw a sharp uptick of 2.38% on December 20, 2024, trading at ₹1,072.75, following the company’s announcement of receiving final approval from the USFDA for its Abbrev...
Alembic Pharmaceuticals secures USFDA approval for Divalproex Sodium Delayed-Release Capsules USP, 125 mg
Alembic Pharmaceuticals Limited, a prominent player in the global pharmaceutical industry, announced on December 20, 2024, that it has received final approval from the United States Food & Drug Admini...
Alembic Pharmaceuticals completes ANVISA GMP Audit for API-II Facility in Brazil
Alembic Pharmaceuticals has recently informed exchanges that the company has successfully completed the GMP audit conducted by the Brazilian Health Regulatory Agency (ANVISA) for its API-II facility i...
Alembic Pharmaceuticals receives tentative USFDA approval for olopatadine hydrochloride solution
Alembic Pharmaceuticals Limited has secured tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for olopatadine hydrochloride ophthalmic s...
Alembic Pharma shares surged nearly 5% today
Alembic Pharmaceuticals shares surged nearly 5% today – as of 9:35 am the shares were trading 4.33% higher at ₹1,086.95 on NSE. Alembic Pharmaceuticals faced a setback as the United States Food and Dr...
Alembic Pharmaceuticals secures USFDA approval for Ivabradine tablets
Alembic Pharmaceuticals Limited (Alembic) recently informed exchanges that the US Food and Drug Administration (USFDA) has granted Final Approval for its Abbreviated New Drug Application (ANDA) Ivabra...
Alembic Pharmaceuticals gains USFDA final approval for Diltiazem Hydrochloride extended-release capsules
Alembic Pharmaceuticals Limited has announced that it has received final approval from the U.S. Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Diltiazem Hydro...
Alembic Pharma Q2 FY25 Results: Revenue jumps 3.3% YoY to ₹1,647.98 crore, net profit jumps 12.2% YoY
Alembic Pharmaceuticals reported its financial results for Q2 FY25, showing positive year-over-year (YoY) growth in both revenue and net profit, though quarter-over-quarter (QoQ) figures reflected mod...
Alembic Pharmaceuticals shares surge today – Know More
Alembic Pharmaceuticals saw a rise in its share price today after announcing that it had received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Applicati...